Successful implementation of outpatient R ± DHAX (rituximab, dexamethasone, oxaliplatin, cytarabine) for select patients with lymphoma: a single-center experience

References

• Joo EH, Rha SY, Ahn JB, et al. Economic and patient-reported outcomes of outpatient home-based versus inpatient hospital-based chemotherapy for patients with colorectal cancer. Support Care Cancer. 2011;19(7):971–978.
   PubMed Web of Science ®Google Scholar
• Robinson WR, Beyer J. Impact of shifting from office- to hospital-based treatment facilities on the administration of intraperitoneal chemotherapy for ovarian cancer. JOP. 2010;6(5):232–235.
   PubMedGoogle Scholar
• Saini L, Minden MD, Schuh AC, et al. Feasibility of outpatient consolidation chemotherapy in older versus younger patients with acute myeloid leukemia. Am J Hematol. 2012;87(3):323–326.
   PubMed Web of Science ®Google Scholar
• Lignon J, Sibon D, Madelaine I, et al. Rituximab, dexamethasone, cytarabine, and oxaliplatin (R-DHAX) is an effective and safe salvage regimen in relapsed/refractory B-cell non-Hodgkin lymphoma. Clin Lymphoma Myeloma Leuk. 2010;10(4):262–269.
   PubMed Web of Science ®Google Scholar
• Rigacci L, Fabbri A, Puccini B, et al. Oxaliplatin-based chemotherapy (dexamethasone, high-dose cytarabine, and oxaliplatin)±rituximab is an effective salvage regimen in patients with relapsed or refractory lymphoma. Cancer. 2010;116(19):4573–4579.
   PubMed Web of Science ®Google Scholar
• Velasquez WS, Cabanillas F, Salvador P, et al. Effective salvage therapy for lymphoma with cisplatin in combination with high-dose Ara-C and dexamethasone (DHAP). Blood. 1988;71(1):117–122.
   PubMed Web of Science ®Google Scholar
• Hermine O, Hoster E, Walewski J, et al. Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma Network. Lancet. 2016;388(10044):565–575.
   PubMed Web of Science ®Google Scholar
• Le Gouill S, Thieblemont C, Oberic L, et al. Rituximab after autologous stem-cell transplantation in mantle-cell lymphoma. N Engl J Med. 2017;377(13):1250–1260.
   PubMed Web of Science ®Google Scholar
• Abali H, Urün Y, Oksüzoğlu B, et al. Comparison of ICE (ifosfamide-carboplatin-etoposide) versus DHAP (cytosine arabinoside-cisplatin-dexamethasone) as salvage chemotherapy in patients with relapsed or refractory lymphoma. Cancer Invest. 2008;26(4):401–406.
   PubMed Web of Science ®Google Scholar
• Gisselbrecht C, Glass B, Mounier N, et al. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J Clin Oncol. 2010;28(27):4184–4190.
   PubMed Web of Science ®Google Scholar
• Witzig TE, Geyer SM, Kurtin PJ, et al. Salvage chemotherapy with rituximab DHAP for relapsed non-Hodgkin lymphoma: a phase II trial in the North Central cancer treatment group. Leuk Lymphoma. 2008;49(6):1074–1080.
   PubMed Web of Science ®Google Scholar
• Hartmann JT, Lipp HP. Toxicity of platinum compounds. Expert Opin Pharmacother. 2003;4(6):889–901.
   PubMed Web of Science ®Google Scholar
• Kanat O, Ozet A, Ataergın S, et al. Modified outpatient dexamethazone, cytarabine and cisplatin regimen may lead to high response rates and low toxicity in lymphoma. Med Princ Pract. 2010;19(5):344–347.
   PubMed Web of Science ®Google Scholar
• Olivieri A, Brunori M, Capelli D, et al. Salvage therapy with an outpatient DHAP schedule followed by PBSC transplantation in 79 lymphoma patients: an intention to mobilize and transplant analysis. Eur J Haematol. 2004;72(1):10–17.
   PubMed Web of Science ®Google Scholar
• Baker WJ, Royer GL, Jr, Weiss RB. Cytarabine and neurologic toxicity. J Clin Oncol. 1991;9(4):679–693.
   PubMed Web of Science ®Google Scholar
• Lazarus HM, Herzig RH, Herzig GP, et al. Central nervous system toxicity of high-dose systemic cytosine arabinoside. Cancer. 1981;48(12):2577–2582.
   PubMed Web of Science ®Google Scholar
• Cheson BD, Fisher RI, Barrington SF, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014;32(27):3059–3068.
   PubMed Web of Science ®Google Scholar
• Keshvani N, Hon M, Gupta A, et al. Reducing hospitalizations: Institution of outpatient infusional EPOCH-Based chemotherapy at a safety net hospital. J Oncol Pract. 2019;15(8):e644–e651.
   PubMed Web of Science ®Google Scholar
• Evans SS, Gandhi AS, Clemmons AB, et al. Clinical and cost comparison evaluation of inpatient versus outpatient administration of EPOCH-containing regimens in non-Hodgkin lymphoma. J Pharm Pract. 2017;30(4):400–405.
   PubMedGoogle Scholar
• McBride A, Campen CJ, Camamo J, et al. Implementation of a pharmacy-managed program for the transition of chemotherapy to the outpatient setting. Am J Health Syst Pharm. 2018;75(9):e246–e258.
   PubMed Web of Science ®Google Scholar
• Allen MR, Aljitawi OS, He J, et al. Outpatient cytarabine administration is safe and effective for consolidation in acute myeloid leukemia. Blood. 2013;122(21):5030–5030.
   Web of Science ®Google Scholar
• Ng C-H, Chen X, Lee F-G, et al. Feasibility of outpatient high dose cytarabine in patients with acute myeloid leukemia. Blood. 2019;134(Supplement_1):2152–2152.
   Google Scholar
• Jafari L, Hussain J, Krishnadasan R, et al. Implementation of outpatient high-dose cytarabine (HiDAC) for AML: evaluation of the impact of transitioned outpatient chemotherapy in an oncology care model setting. Blood. 2019;134(supplement_1):2153–2153.
   Google Scholar
• Efficace FK, Vignetti M, Mandelli F, et al. Health-related quality of life assessment and reported outcomes in leukaemia randomised controlled trials – a systematic review to evaluate the added value in supporting clinical decision making. Eur J Cancer. 2008;44(11):1497–1506.
   PubMed Web of Science ®Google Scholar
• Hill H, Arnall J, Janes A, et al. A review of R-DHAP administration in the outpatient setting and a case of the alternative regimen R-DHAX given outpatient for refractory diffuse large B-cell lymphoma. J Oncol Pharm Pract. 2019;25(8):2041–2044.
   PubMed Web of Science ®Google Scholar